PamGene shares experience on biomarker development and ICI therapy response prediction at Cancer Bioinformatics Symposium

The 1st Annual Cancer Bioinformatics Symposium at the University of Toledo College of Medicine and Life Sciences will take place February 5th. The full day, online event champions collaboration between basic science cancer researchers and bioinformaticians. An international panel of research scientists will include speakers from premier academic laboratories, biomedical industry, and the National Cancer Institute.

PamGene’s CEO, Prof. Dr. John P. Groten, and Head of Diagnostic Assay Services, Rik de Wijn, PhD, will share their knowledge and experience on biomarker development in cancer and how to apply this technology to predict a patient’s response to checkpoint inhibitors.

Challenges in Biomarker Development in Cancer
Speaker: Prof. Dr. John P. Groten
Managing Director, PamGene International, the Netherlands 
9:05 AM to 9:20 AM (15 minutes)

Blood based kinome profiling of immune cells to predict the response to checkpoint inhibitors in cancer
Speaker: Rik de Wijn, PhD
Head of Diagnostic Assay Services, PamGene International BV, The Netherlands
9:20 AM to 10:00 AM (30-minute talk + 10-minutes question and answer segment)

Related Posts